Lumos Pharma Inc LUMO

Healthcare Biotechnology

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.

NDAQ:LUMO - Post by User

Lumos Pharma Inc

<< Previous

Bullboard Posts

Post by whytestockson Feb 26, 2024 8:15pm

32 Views

Post# 35900434

Lumos Pharma to Report Full Year 2023 Financial Results and

JUST IN: $LUMO Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results ...LUMO - Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

<< Previous

Bullboard Posts

Rock Tech notches official permit for German lithium refinery